Mayo Test Catalog, (Sorted By Test Name) - Mayo Medical ...

89710
LOX
80462
FLCA
60619
Low-Grade Fibromyxoid Sarcoma, 16p11 (FUS or TLS)
Rearrangement, FISH, Tissue
Clinical Information: Low-grade fibromyxoid sarcoma (LGFMS) is a rare malignant soft tissue
tumor characterized by a bland fibroblastic spindle cell proliferation arranged in alternating fibrous and
myxoid areas, with or without giant collagen rosettes. These tumors are characterized by the
chromosome translocation t(7;16)(q33-34;p11), which results in the fusion of FUS (also called TLS) on
chromosome 16 to CREB3L2 (also called BBF2H7) on chromosome 7. Greater than 70% of LGFMS
are cytogenetically characterized by this translocation. In rare cases, a variant t(11;16) (p11;p11) has
been described in which FUS is fused to CREB3L1 (OASIS), a gene structurally related to CREB3L2.
Testing of FUS locus rearrangement should be concomitant with histologic evaluation, and positive
results may support the diagnosis of LGFMS.
Useful For: Aiding in the diagnosis of low-grade fibromyxoid sarcoma when used in conjunction
with an anatomic pathology consultation
Interpretation: A neoplastic clone is detected when the percent of cells with an abnormality exceeds
the normal cutoff for the FUS probe set. A positive result is consistent with the diagnosis of low-grade
fibromyxoid sarcoma (LGFMS). A negative result suggests that a FUS gene rearrangement is not
present, but does not exclude the diagnosis of LGFMS.
Reference Values:
An interpretative report will be provided.
Loxapine (Loxitaner) and 8-Hydroxyloxapine
Reference Values:
Loxapine:
Reference Range: 5.0 - 30.0 ng/mL
8-Hydroxyloxapine:
Reference Range: 20.0 - 100.0 ng/mL
Test Performed By:
Medtox Laboratories, Inc.
402 W. County Road D
St. Paul, MN 55112
Lung Cancer, ALK (2p23) Rearrangement, FISH, Tissue
Clinical Information: Lung cancer is the leading cause of cancer death in the United States.
Non-small cell lung carcinoma (NSCLC) accounts for 75% to 80% of all lung cancers with an overall
5-year survival rate of 10% to 15%. Standard chemotherapy regimens have had marginal success in
improving clinical outcomes. Targeted treatments may be used as novel molecular changes are
identified. Rearrangements of the ALK locus are found in a subset of lung carcinomas and their
identification may guide important therapeutic decisions for the management of these tumors. The
fusion of EML4 (echinoderm microtubule-associated protein-like 4) gene with the ALK (anaplastic
large cell lymphoma kinase) gene results from an inversion of chromosome band 2p23. The
ALK-EML4 rearrangement has been identified in 3% to 5% of NSCLC with the majority in
adenocarcinoma and younger male patients who were light or nonsmokers. Recent studies have
demonstrated that lung cancers harboring ALK rearrangements are resistant to epidermal growth factor
receptor tyrosine kinase inhibitors, but may be highly sensitive to ALK inhibitors, like Xalkori
(crizotinib).The drug Xalkori works by blocking certain kinases, including those produced by the
abnormal ALK gene. Clinical studies have demonstrated that Xalkori treatment of patients with tumors
Current as of January 3, 2013 2:22 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1127